CEA Grants NEB License to Patent that Covers a Process for Synthesis of Double Stranded RNA
News Feb 28, 2006
The CEA, a French government-funded research organisation, has announced that its life science division has granted New England Biolabs Inc. a non-exclusive license under the patent family EP10618966.
This license concerns some RNAi products that NEB supplies to its customers in the research reagent field.
This patent family, owned solely by the CEA, covers a process for an enzymatic synthesis of double-stranded RNA based on the transcription of a double-stranded DNA template.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.